Annual Revenue
$528.29 M
+$128.94 M+32.29%
December 31, 2024
Summary
- As of March 1, 2025, FOLD annual revenue is $528.29 million, with the most recent change of +$128.94 million (+32.29%) on December 31, 2024.
- During the last 3 years, FOLD annual revenue has risen by +$222.78 million (+72.92%).
- FOLD annual revenue is now at all-time high.
Performance
FOLD Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Revenue
$149.71 M
+$8.19 M+5.79%
December 31, 2024
Summary
- As of March 1, 2025, FOLD quarterly revenue is $149.71 million, with the most recent change of +$8.19 million (+5.79%) on December 31, 2024.
- Over the past year, FOLD quarterly revenue has increased by +$34.62 million (+30.09%).
- FOLD quarterly revenue is now at all-time high.
Performance
FOLD Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
TTM Revenue
$528.29 M
+$34.62 M+7.01%
December 31, 2024
Summary
- As of March 1, 2025, FOLD TTM revenue is $528.29 million, with the most recent change of +$34.62 million (+7.01%) on December 31, 2024.
- Over the past year, FOLD TTM revenue has increased by +$128.94 million (+32.29%).
- FOLD TTM revenue is now at all-time high.
Performance
FOLD TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
FOLD Revenue Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +32.3% | +30.1% | +32.3% |
| 3 y3 years | +72.9% | +44.6% | +41.9% |
| 5 y5 years | +189.9% | +44.6% | +41.9% |
FOLD Revenue Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +72.9% | at high | +90.2% | at high | +72.9% |
| 5 y | 5-year | at high | +189.9% | at high | +170.8% | at high | +189.9% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% | at high | >+9999.0% |
Amicus Therapeutics Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $528.29 M(+32.3%) | $149.71 M(+5.8%) | $528.29 M(+7.0%) |
| Sep 2024 | - | $141.52 M(+11.7%) | $493.67 M(+8.3%) |
| Jun 2024 | - | $126.67 M(+14.7%) | $455.65 M(+7.6%) |
| Mar 2024 | - | $110.40 M(-4.1%) | $423.49 M(+6.0%) |
| Dec 2023 | $399.36 M(+21.3%) | $115.08 M(+11.2%) | $399.36 M(+7.2%) |
| Sep 2023 | - | $103.50 M(+9.5%) | $372.37 M(+6.2%) |
| Jun 2023 | - | $94.50 M(+9.5%) | $350.56 M(+4.1%) |
| Mar 2023 | - | $86.27 M(-2.1%) | $336.79 M(+2.3%) |
| Dec 2022 | $329.23 M(+7.8%) | $88.10 M(+7.8%) | $329.23 M(+1.8%) |
| Sep 2022 | - | $81.69 M(+1.2%) | $323.29 M(+0.7%) |
| Jun 2022 | - | $80.73 M(+2.6%) | $321.14 M(+1.0%) |
| Mar 2022 | - | $78.72 M(-4.2%) | $317.83 M(+4.0%) |
| Dec 2021 | $305.51 M(+17.1%) | $82.15 M(+3.3%) | $305.51 M(+3.9%) |
| Sep 2021 | - | $79.55 M(+2.8%) | $293.93 M(+4.3%) |
| Jun 2021 | - | $77.41 M(+16.6%) | $281.82 M(+5.6%) |
| Mar 2021 | - | $66.40 M(-5.9%) | $266.76 M(+2.3%) |
| Dec 2020 | $260.89 M(+43.2%) | $70.57 M(+4.6%) | $260.89 M(+6.2%) |
| Sep 2020 | - | $67.44 M(+8.2%) | $245.61 M(+8.2%) |
| Jun 2020 | - | $62.35 M(+3.0%) | $226.94 M(+8.7%) |
| Mar 2020 | - | $60.52 M(+9.5%) | $208.72 M(+14.5%) |
| Dec 2019 | $182.24 M(+99.7%) | $55.29 M(+13.4%) | $182.24 M(+14.2%) |
| Sep 2019 | - | $48.77 M(+10.5%) | $159.59 M(+21.4%) |
| Jun 2019 | - | $44.13 M(+29.6%) | $131.42 M(+21.0%) |
| Mar 2019 | - | $34.05 M(+4.3%) | $108.59 M(+19.0%) |
| Dec 2018 | $91.25 M(+147.1%) | $32.64 M(+58.5%) | $91.25 M(+24.4%) |
| Sep 2018 | - | $20.60 M(-3.3%) | $73.33 M(+15.3%) |
| Jun 2018 | - | $21.31 M(+27.6%) | $63.61 M(+28.6%) |
| Mar 2018 | - | $16.70 M(+13.4%) | $49.46 M(+33.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2017 | $36.93 M(+644.9%) | $14.73 M(+35.5%) | $36.93 M(+47.5%) |
| Sep 2017 | - | $10.87 M(+51.9%) | $25.03 M(+53.7%) |
| Jun 2017 | - | $7.16 M(+71.7%) | $16.29 M(+78.4%) |
| Mar 2017 | - | $4.17 M(+47.3%) | $9.13 M(+84.1%) |
| Dec 2016 | $4.96 M(+305.1%) | $2.83 M(+33.1%) | $4.96 M(+133.1%) |
| Sep 2016 | - | $2.13 M(+625.9%) | $2.13 M(+37.4%) |
| Dec 2014 | $1.22 M(+237.2%) | - | - |
| Sep 2014 | - | $293.00 K(-38.3%) | $1.55 M(+19.6%) |
| Jun 2014 | - | $475.00 K(+4.2%) | $1.29 M(+58.0%) |
| Mar 2014 | - | $456.00 K(+40.7%) | $819.00 K(+125.6%) |
| Dec 2013 | $363.00 K(-98.0%) | $324.00 K(+730.8%) | $363.00 K(+830.8%) |
| Sep 2013 | - | $39.00 K(-99.6%) | $39.00 K(-99.9%) |
| Dec 2012 | $18.41 M(-14.1%) | - | - |
| Jun 2012 | - | $10.64 M(+36.8%) | $29.84 M(+28.4%) |
| Mar 2012 | - | $7.77 M(+38.1%) | $23.24 M(+8.4%) |
| Dec 2011 | $21.43 M(+2224.7%) | $5.63 M(-2.9%) | $21.43 M(+28.1%) |
| Sep 2011 | - | $5.80 M(+43.5%) | $16.73 M(+53.1%) |
| Jun 2011 | - | $4.04 M(-32.3%) | $10.93 M(+58.7%) |
| Mar 2011 | - | $5.97 M(+547.1%) | $6.89 M(+647.1%) |
| Dec 2010 | $922.00 K(-98.6%) | $922.00 K(-98.1%) | $922.00 K(-98.6%) |
| Dec 2009 | $64.36 M(+330.0%) | $49.48 M(+907.0%) | $64.36 M(+234.8%) |
| Sep 2009 | - | $4.91 M(-8.4%) | $19.23 M(+7.0%) |
| Jun 2009 | - | $5.36 M(+16.4%) | $17.96 M(+9.5%) |
| Mar 2009 | - | $4.61 M(+6.0%) | $16.41 M(+9.7%) |
| Dec 2008 | $14.97 M(+739.0%) | $4.34 M(+18.9%) | $14.96 M(+40.9%) |
| Sep 2008 | - | $3.65 M(-4.0%) | $10.62 M(+52.4%) |
| Jun 2008 | - | $3.81 M(+20.5%) | $6.97 M(+120.5%) |
| Mar 2008 | - | $3.16 M | $3.16 M |
| Dec 2007 | $1.78 M | - | - |
FAQ
- What is Amicus Therapeutics annual revenue?
- What is the all time high annual revenue for Amicus Therapeutics?
- What is Amicus Therapeutics annual revenue year-on-year change?
- What is Amicus Therapeutics quarterly revenue?
- What is the all time high quarterly revenue for Amicus Therapeutics?
- What is Amicus Therapeutics quarterly revenue year-on-year change?
- What is Amicus Therapeutics TTM revenue?
- What is the all time high TTM revenue for Amicus Therapeutics?
- What is Amicus Therapeutics TTM revenue year-on-year change?
What is Amicus Therapeutics annual revenue?
The current annual revenue of FOLD is $528.29 M
What is the all time high annual revenue for Amicus Therapeutics?
Amicus Therapeutics all-time high annual revenue is $528.29 M
What is Amicus Therapeutics annual revenue year-on-year change?
Over the past year, FOLD annual revenue has changed by +$128.94 M (+32.29%)
What is Amicus Therapeutics quarterly revenue?
The current quarterly revenue of FOLD is $149.71 M
What is the all time high quarterly revenue for Amicus Therapeutics?
Amicus Therapeutics all-time high quarterly revenue is $149.71 M
What is Amicus Therapeutics quarterly revenue year-on-year change?
Over the past year, FOLD quarterly revenue has changed by +$34.62 M (+30.09%)
What is Amicus Therapeutics TTM revenue?
The current TTM revenue of FOLD is $528.29 M
What is the all time high TTM revenue for Amicus Therapeutics?
Amicus Therapeutics all-time high TTM revenue is $528.29 M
What is Amicus Therapeutics TTM revenue year-on-year change?
Over the past year, FOLD TTM revenue has changed by +$128.94 M (+32.29%)